NCT04594005 |
|
CDK46 Tumor Abemaciclib Paclitaxel
|
View
|
NCT02290145 |
|
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
|
View
|
NCT05382585 |
|
Newer Therapeutic Targets in Head and Neck Cancers
|
View
|
NCT03356223 |
|
Evaluation of ABEMACICLIB Monotherapy in Patients With Locally AdvancedMetastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A andor an Amplification of CCND1 andor of CDK6
|
View
|
NCT04439201 |
|
Testing Palbociclib PD-0332991 as a Potential Targeted Treatment in Cancers With CCND1 2 3 Amplification MATCH-Subprotocol Z1B
|
View
|
NCT02508467 |
|
A Phase 1 Study of Fisogatinib BLU-554 in Patients With Hepatocellular Carcinoma
|
View
|
NCT03310879 |
|
Study of the CDK46 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6
|
View
|
NCT03454919 |
|
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
|
View
|